156 related articles for article (PubMed ID: 33385522)
1. Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis.
Kittipibul V; Blumer V; Angsubhakorn N; Hernandez GA; Chaparro S; Tedford RJ; Agarwal R
J Card Fail; 2021 Apr; 27(4):477-485. PubMed ID: 33385522
[TBL] [Abstract][Full Text] [Related]
2. Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.
Gulati G; Grandin EW; Kennedy K; Cabezas F; DeNofrio DD; Kociol R; Rame JE; Pagani FD; Kirklin JK; Kormos RL; Teuteberg J; Kiernan M
Circ Heart Fail; 2019 Jun; 12(6):e005537. PubMed ID: 31181953
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase-5 inhibitors for left ventricular assist device implantation complicated by right ventricular failure.
Papathanasiou M; Jakstaite AM; Mincu R; Wernhart S; Ruhparwar A; Rassaf T; Luedike P
ESC Heart Fail; 2023 Aug; 10(4):2728-2733. PubMed ID: 37056058
[TBL] [Abstract][Full Text] [Related]
4. Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation.
Jakstaite AM; Luedike P; Schmack B; Pizanis N; Riebisch M; Weymann A; Kamler M; Ruhparwar A; Rassaf T; Papathanasiou M
ESC Heart Fail; 2021 Aug; 8(4):2419-2427. PubMed ID: 33821578
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
[TBL] [Abstract][Full Text] [Related]
6. Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis.
Grandin EW; Gulati G; Nunez JI; Kennedy K; Rame JE; Atluri P; Pagani FD; Kirklin JK; Kormos RL; Teuteberg J; Kiernan MS
Circ Heart Fail; 2022 Apr; 15(4):e008613. PubMed ID: 35332780
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
De Vecchis R; Cesaro A; Ariano C
Minerva Cardioangiol; 2018 Oct; 66(5):659-670. PubMed ID: 28398017
[TBL] [Abstract][Full Text] [Related]
8. Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.
Xanthopoulos A; Tryposkiadis K; Triposkiadis F; Fukamachi K; Soltesz EG; Young JB; Wolski K; Blackstone EH; Starling RC
J Am Heart Assoc; 2020 Jul; 9(14):e015897. PubMed ID: 32648508
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative atrial fibrillation and early right ventricular failure after left ventricular assist device implantation: a systematic review and meta-analysis.
Kittipibul V; Blumer V; Hernandez GA; Fudim M; Flowers R; Chaparro S; Agarwal R
Am Heart J; 2021 Sep; 239():120-128. PubMed ID: 34038705
[TBL] [Abstract][Full Text] [Related]
10. Sex disparities in left ventricular assist device implantation outcomes: A systematic review and meta-analysis of over 50 000 patients.
Arjomandi Rad A; Kapadia S; Zubarevich A; Nanchahal S; Van den Eynde J; Vardanyan R; Bareka M; Krasopoulos G; Quarto C; Ruhparwar A; Athanasiou T; Weymann A
Artif Organs; 2023 Feb; 47(2):273-289. PubMed ID: 36461903
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation.
Baker WL; Radojevic J; Gluck JA
Artif Organs; 2016 Feb; 40(2):123-8. PubMed ID: 26043796
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil in Left Ventricular Assist Device Is Safe and Well-Tolerated.
Ravichandran AK; LaRue SJ; Novak E; Joseph SA; Schilling JD
ASAIO J; 2018; 64(2):280-281. PubMed ID: 28692527
[TBL] [Abstract][Full Text] [Related]
13. Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies.
Bellavia D; Iacovoni A; Scardulla C; Moja L; Pilato M; Kushwaha SS; Senni M; Clemenza F; Agnese V; Falletta C; Romano G; Maalouf J; Dandel M
Eur J Heart Fail; 2017 Jul; 19(7):926-946. PubMed ID: 28371221
[TBL] [Abstract][Full Text] [Related]
14. Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices.
Xanthopoulos A; Wolski K; Wang Q; Blackstone EH; Randhawa VK; Soltesz EG; Young JB; Nissen SE; Estep JD; Triposkiadis F; Starling RC
JACC Heart Fail; 2022 Feb; 10(2):89-100. PubMed ID: 35115092
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Adverse Events With Phosphodiesterase 5 Inhibitors Post LVAD Implantation: Is It Time for a Randomized Trial?
Starling RC; Xanthopoulos A; Nissen SE; Triposkiadis F
J Card Fail; 2022 Dec; 28(12):1733-1737. PubMed ID: 35690316
[TBL] [Abstract][Full Text] [Related]
17. Post-Implant Phosphodiesterase-5 Inhibitors in Patients with Left Ventricular Assist Device: A Systematic Review and Meta-Analysis.
Xanthopoulos A; Magouliotis DE; Tryposkiadis K; Zotos PA; Spiliopoulos K; Athanasiou T; Giamouzis G; Skoularigis J; Starling RC; Triposkiadis F
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294308
[TBL] [Abstract][Full Text] [Related]
18. A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure.
Cavarretta E; Marullo AGM; Sciarretta S; Benedetto U; Greco E; Roever L; Tonelli E; Peruzzi M; Iaccarino A; Biondi-Zoccai G; Frati G
Eur J Cardiothorac Surg; 2019 Mar; 55(3):461-467. PubMed ID: 30137270
[TBL] [Abstract][Full Text] [Related]
19. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
Giannetta E; Feola T; Gianfrilli D; Pofi R; Dall'Armi V; Badagliacca R; Barbagallo F; Lenzi A; Isidori AM
BMC Med; 2014 Oct; 12():185. PubMed ID: 25330139
[TBL] [Abstract][Full Text] [Related]
20. Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor.
Hamdan R; Mansour H; Nassar P; Saab M
Artif Organs; 2014 Nov; 38(11):963-7. PubMed ID: 24689700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
